|
|
||||||||
in NCI-H295R adrenocortical cells
1 Departments of Pathology and
2 Virology, Haartman Institute, University of Helsinki, Helsinki, Finland
3 Department of Pediatrics, Kuopio University and University Hospital, Kuopio, Finland
(Requests for offprints should be addressed to J Liu, Department of Pathology, Haartman Institute, P.O. Box 21, University of Helsinki, FIN-00014 Helsinki, Finland; Email: Jiangi.Liu{at}helsinki.fi)
(J Liu and X-D Li contributed equally to this work)
Adrenocorticotropin is the major regulator of adrenocortical development and function. It acts mainly through the cAMP-dependent protein kinase A (PKA) pathway. Our aim was to study the interaction of tumor necrosis factor-
(TNF
) and the PKA pathway in adrenocortical cell proliferation and apoptosis. The PKA activator Dibutyryl cAMP ((Bu)2cAMP) strongly induced differentiation and inhibited proliferation in the human adrenocortical cell line NCI-H295R (H295R). TNF
induced apoptosis of H295R cells. Interestingly, (Bu)2cAMP treatment clearly enhanced TNF
-induced apoptosis in H295R cells, but not in another human adrenocortical cell line SW-13, the mouse adrenocortical Y-1 cell line or the human HeLa cell line. This synergistic effect was not due to the (Bu)2cAMP-induced glucocorticoid secretion since dexamethasone had no significant effect on the TNF
-induced apoptosis. (Bu)2cAMP treatment rapidly increased the expression of the proto-oncogene c-myc in H295R cells, but not in SW-13, Y-1 or HeLa cells. In transient c-myc transfection assay, c-myc expression associated with decreased expression of the proliferation marker Ki-67 in H295R cells. In conclusion, cAMP-dependent protein kinase activation reduced proliferation and augmented TNF
-induced apoptosis in adrenocortical H295R cells, and these effects were associated with increased c-myc expression.
This article has been cited by other articles:
![]() |
I. V. Mikhaylova, T. Kuulasmaa, J. Jaaskelainen, and R. Voutilainen Tumor Necrosis Factor-{alpha} Regulates Steroidogenesis, Apoptosis, and Cell Viability in the Human Adrenocortical Cell Line NCI-H295R Endocrinology, January 1, 2007; 148(1): 386 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Kirschner Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 14 - 21. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |